peptideInjectablePrescription only (US)FDA-approved only for HIV-associated lipodystrophy
TesamorelinBenefits, Dosage & Interactions
Tesamorelin is a synthetic peptide that mimics human growth hormone-releasing hormone (GHRH). It is approved for the treatment of excess abdominal fat in adult patients with HIV-associated lipodystrophy. Research on Tesamorelin focuses on heart and circulatory health and cognition and mood.
How much Tesamorelin do people take?
2 mg once daily was the amount used across the pivotal trials. Route reported: Subcutaneous injection into the abdomen. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Tesamorelin — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Plasma half-life
~0.4 h
Typical timing
in the evening
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Tesamorelin in the cited sources. Published ranges are not dosing advice.
Mixing Tesamorelin: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 2 mg vial and a 100 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 100 mcg draws to |
|---|---|---|
| 1 mL | 2 mg/mL | 5 units |
| 2 mL | 1 mg/mL | 10 units |
| 3 mL | 0.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, Tesamorelin vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
Tesamorelin compared with similar compounds
| Attribute | Sermorelin | Tesamorelin | CJC-1295 | Ipamorelin |
|---|---|---|---|---|
| Class | GHRH (1-29) analog | Stabilized GHRH analog | GHRH analog (DAC-conjugated) | Selective ghrelin receptor (GHS-R) agonist |
| Route | Subcutaneous injection | Subcutaneous once daily | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~11–12 minutes | ~26–38 minutes | ~5.8–8 days with DAC | ~2 hours |
| Evidence grade | Moderate | Strong | Limited | Preclinical |
| Oral stability | Not orally available | Not orally available | Not orally available | Not orally available |
| Typical published cycle | Daily dosing in published studies | 26–52 weeks in the pivotal trials | Weekly dosing in the published phase 1 work | No established human protocol |
| Main studied use | Growth hormone secretion / GH deficiency testing | HIV-associated visceral adiposity | Sustained GH/IGF-1 elevation | Selective GH release without prolactin/cortisol rise |
References & evidence
Documents the Tesamorelin entry is written from. Each number matches an inline marker above.
- [1]Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fatFalutz J, Mamputu JC, Potvin D, et al. · Journal of Clinical Endocrinology & Metabolism · 2010 · Peer-reviewed · PMID 20554713
- [2]Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelinStanley TL, Falutz J, Marsolais C, et al. · Clinical Infectious Diseases · 2012 · Peer-reviewed · PMID 22495074
References & Evidence
Sources on this page that document Tesamorelin dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Tesamorelin studied for?
What is Tesamorelin?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Tesamorelin is a synthetic peptide that mimics human growth hormone-releasing hormone (GHRH). It is approved for the treatment of excess abdominal fat in adult patients with HIV-associated lipodystrophy. This condition is characterized by changes in body fat distribution, including visceral adiposity (accumulation of fat around internal organs), and can be a side effect of antiretroviral therapy (National Institutes of Health Clinical Center). Tesamorelin works by stimulating the natural production and release of growth hormone from the pituitary gland. Its structure is similar to naturally occurring GHRH, but with a modification that makes it more stable in the body, allowing for sustained action (DrugBank). It is administered via subcutaneous injection.
What does the research say about Tesamorelin?
Tap a section to expand.
Tesamorelin's primary mechanism of action involves binding to and activating growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland. This binding stimulates the pituitary to synthesize and release endogenous growth hormone (GH). Growth hormone, in turn, exerts various effects throughout the body. Specifically, GH acts on target tissues, including the liver, where it promotes the production of insulin-like growth factor 1 (IGF-1). Both GH and IGF-1 play crucial roles in metabolism, influencing lipid and glucose homeostasis. In the context of HIV-associated lipodystrophy, Tesamorelin's ability to increase GH and IGF-1 levels is thought to contribute to the reduction of visceral adipose tissue (VAT), the deep abdominal fat associated with metabolic complications (FDA Prescribing Information). The exact sequence of events leading to VAT reduction is complex and likely involves alterations in lipid metabolism, fat oxidation, and perhaps improvements in insulin sensitivity, though these are still areas of ongoing research. Tesamorelin does not directly influence viral load or immune function in HIV patients.
Source for this section: Sources for How does Tesamorelin work?: Jumps to this entry in the sources and references list at the end of the page.
The primary established benefit of Tesamorelin is the reduction of excess visceral abdominal fat in adult patients with HIV-associated lipodystrophy. Clinical trials, as summarized by the FDA Prescribing Information, have demonstrated that Tesamorelin treatment leads to statistically significant and clinically meaningful decreases in waist circumference and visceral adipose tissue (VAT) area compared to placebo. This reduction in VAT is important as excess visceral fat is linked to an increased risk of cardiovascular disease and metabolic abnormalities, such as insulin resistance and dyslipidemia, in HIV-infected individuals. Beyond fat reduction, some studies have also indicated potential improvements in lipid profiles, including reductions in triglycerides and total cholesterol, and improvements in the ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol (PubChem). However, the direct impact of Tesamorelin on cardiovascular outcomes has not been established. There is also evidence suggesting that Tesamorelin may improve bone mineral density and cognitive function in some populations, but these are considered investigational uses and are not approved indications for the drug in the context of HIV-associated lipodystrophy (Examine.com). The main focus of its therapeutic use remains the management of abnormal fat distribution.
Clinical evidence supporting the use of Tesamorelin primarily stems from randomized, placebo-controlled trials in adults with HIV-associated lipodystrophy. These studies consistently demonstrated that Tesamorelin significantly reduced visceral adipose tissue (VAT) compared to placebo (FDA Prescribing Information, Cochrane Review). For instance, a meta-analysis of relevant studies found a consistent reduction in VAT area, as measured by CT scans, in patients receiving Tesamorelin. These studies typically involved daily subcutaneous injections for 26 weeks or longer. While primarily focused on VAT reduction, secondary outcomes often included changes in waist circumference, lipid parameters, and quality of life. Some trials reported favorable changes in triglycerides and cholesterol levels, although the long-term clinical significance of these lipid changes on cardiovascular risk requires further investigation (PubChem). The sustained effect of Tesamorelin after discontinuation of treatment is limited, suggesting that continued administration is often necessary to maintain the reduction in visceral fat. The evidence base for Tesamorelin is considered robust for its approved indication, drawing from well-designed clinical trials that have met regulatory standards. However, its effectiveness and safety in populations beyond HIV-associated lipodystrophy are not as well-established and remain areas of ongoing research.
Commonly reported side effects of Tesamorelin are generally manageable and localized to the injection site. These include redness, itching, pain, swelling, and bruising at the injection site. Other frequently observed side effects can include hypersensitivity reactions such as rash and hives, arthralgia (joint pain), myalgia (muscle pain), and peripheral edema (swelling of the extremities). Headaches, flushing, and increased glucose levels have also been reported in clinical trials (FDA Prescribing Information, MedlinePlus). Pituitary enlargement has been noted in some individuals, though it is usually asymptomatic. More serious but less common side effects can include severe allergic reactions (anaphylaxis), and changes in glucose tolerance or the onset of new-onset diabetes. Patients with pre-existing diabetes may experience worsening glycemic control. Due to its mechanism of stimulating growth hormone, Tesamorelin can sometimes lead to an increase in IGF-1 levels beyond the normal range, which requires monitoring. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Tesamorelin can cause hypersensitivity reactions, including serious systemic allergic reactions such as anaphylaxis; patients should be advised of the signs and symptoms and to seek immediate medical attention if they occur. It has also been associated with increases in fasting plasma glucose and glycosylated hemoglobin (HbA1c) in some patients, necessitating careful monitoring, especially in individuals with diabetes or those at risk of developing diabetes. Patients should be monitored for potential development of type 2 diabetes during treatment (FDA Prescribing Information). There have been reports of injection site reactions which can typically be managed with local treatment. Fluid retention, manifesting as peripheral edema, arthralgia, or carpal tunnel syndrome, can occur and may warrant dose adjustment or discontinuation of treatment. Tesamorelin is not indicated for weight loss in patients who do not have HIV-associated lipodystrophy. Use in pregnant or breastfeeding women has not been adequately studied and is not recommended. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Tesamorelin is contraindicated in individuals with a known hypersensitivity to Tesamorelin or to any of its excipients. It is also contraindicated in patients with active malignancy (either newly diagnosed or recurrent) due to concerns that growth hormone-releasing hormone analogs could stimulate tumor growth. Before initiating Tesamorelin therapy, a thorough oncologic evaluation is recommended to rule out pre-existing malignancies (FDA Prescribing Information). Additionally, Tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis, which could affect the pituitary's ability to respond to GHRH. Severe renal or hepatic impairment may also be considered a contraindication or require close monitoring, although specific guidelines vary. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Concomitant use of Tesamorelin with exogenous growth hormone is not recommended and could lead to excessive levels of growth hormone and insulin-like growth factor 1 (IGF-1), increasing the risk of adverse effects. Care should be exercised when co-administering Tesamorelin with medications that affect the pituitary gland or growth hormone secretion, as this could alter the therapeutic response or side effect profile. Specifically, glucocorticoids can suppress the response of the pituitary to GHRH, potentially reducing the effectiveness of Tesamorelin. Conversely, some medications, such as anabolic steroids, might interact with growth hormone pathways, requiring careful consideration. Patients with diabetes or those taking insulin or oral hypoglycemic agents should be closely monitored as Tesamorelin can alter glucose metabolism (MedlinePlus). Adjustments to diabetic medication may be necessary. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Tesamorelin is typically administered once daily via subcutaneous injection. The timing often involves administration at bedtime, as this aligns with the natural pulsatile release of growth hormone during sleep. It can be taken with or without food. However, consistency in daily administration time is generally advised for optimal therapeutic effect and to maintain stable drug levels. Dose is user-directed and must be set by a licensed clinician.
Source for this section: Sources for When should you take Tesamorelin?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Tesamorelin is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Tesamorelin?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| IGF-1 LR3 | Caution | Compound pairConfidence: theoretical | These do NOT oppose each other — both push the GH/IGF-1 axis the same direction. Tesamorelin raises your own GH and IGF-1; IGF-1 LR3 adds exogenous IGF-1. Stacking is redundant, risks overstimulation, and the added IGF-1 can suppress natural GH via feedback, partly working against the tesamorelin.Source pending | Same-axis redundancy, not synergy — don't stack without a clear reason and provider oversight. |
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Tesamorelin
Tesamorelin is used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a condition involving changes in body fat distribution that can occur in HIV patients.
Tesamorelin works by mimicking a natural hormone (GHRH) to stimulate the body's own pituitary gland to make and release growth hormone, which helps reduce visceral fat.
Yes, Tesamorelin is administered as a subcutaneous injection, usually once daily.
Common side effects include injection site reactions (redness, pain, itching), joint pain, muscle pain, and peripheral swelling. Headaches and changes in blood sugar can also occur.
No, Tesamorelin does not treat HIV infection itself and does not affect the viral load. It only addresses the symptom of abnormal fat accumulation known as lipodystrophy.
As a peptide, Tesamorelin can overlap with other supplements, prescription medicines, hormones and peptides. Because Tesamorelin is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 0.4 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Tesamorelin with no sign-up.
Tesamorelin is typically taken in the evening. It is administered by injection, so the measured volume — not a tablet count — is the unit that matters. The reported plasma half-life is about 0.4 hours, which is what drives how often it is redosed. It is a controlled substance in some jurisdictions, so the prescribed amount is the only appropriate one. Amounts for this peptide vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.
Whether Tesamorelin fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Tesamorelin. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 0.4 hours is why protocols often split Tesamorelin across the day rather than using a single dose. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Tesamorelin clears quickly (plasma half-life around 0.4 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Tesamorelin the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
2 mg once daily was the amount used across the pivotal trials. Route reported: Subcutaneous injection into the abdomen. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Tesamorelin — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Tesamorelin?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors(opens PubMed in a new tab)AIDS · 2024 · PMID 38905488 · https://pubmed.ncbi.nlm.nih.gov/38905488/
- 2.Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy(opens PubMed in a new tab)Drugs · 2011 · PMID 21668043 · https://pubmed.ncbi.nlm.nih.gov/21668043/
- 3.Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity(opens PubMed in a new tab)J Infect Dis · 2025 · PMID 39813152 · https://pubmed.ncbi.nlm.nih.gov/39813152/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 16137828(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/16137828
Verify at
Publisher search links for Tesamorelin. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Tesamorelin?
Plain-text summary, safe to quote verbatim:
Tesamorelin is a synthetic peptide that mimics human growth hormone-releasing hormone (GHRH). It is approved for the treatment of excess abdominal fat in adult patients with HIV-associated lipodystrophy. Research on Tesamorelin focuses on heart and circulatory health and cognition and mood.
Source: DoseRoutine — https://doseroutine.com/library/tesamorelin
Tesamorelin cheat sheet
DoseRoutine cheat sheet · Peptide
Tesamorelin
Tesamorelin is a synthetic peptide that mimics human growth hormone-releasing hormone (GHRH). It is approved for the treatment of excess abdominal fat in adult patients with HIV-associated lipodystrophy.
Evidence
Strong
2 human randomized trials and regulatory approval on file.
Studied range
2 mg once daily was the amount used across the pivotal trials
Route
Subcutaneous injection into the abdomen
Frequency studied
Once daily
Half-life
~0.4 h
Timing
in the evening
Storage
Supplied lyophilized and reconstituted immediately before injection in the trial protocol
Prescription only (US)FDA-approved only for HIV-associated lipodystrophyCardiovascularBrain
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/tesamorelin
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Tesamorelin — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/tesamorelin
What compounds are similar to Tesamorelin?
Others in the peptide category or studied for the same goals.
Which goals is Tesamorelin used for?
Other compounds studied for the same benefits as Tesamorelin.
Heart & Circulation
See all →Continue exploring
See every compound DoseRoutine catalogs for these goals.